Audit: QRS - L-Theanine for Health & Longevity

Audit conducted on 28/08/2026 17:12 using AI4L + evidence-mcp / Opus 5

Iterations

Summary

Items Count
Total 93
Passed 84
Failed 0
N/A 9
Pass Rate 100.00%
  • Total = Passed + Failed + N/A
  • Pass Rate = Passed / (Passed + Failed) × 100
  • N/A items are excluded from the pass rate calculation

1. General Rules

# Description Result Comments
1.1 Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. 🟢 Every populated span traces to ER text: at-a-glance to Conclusion, protocol cells to Therapeutic Protocol, time cells to Practical Considerations, benefit/risk tiers to their ER headings, gates to Key Interactions & Contraindications, monitoring rows to the ER biomarker table.
1.2 Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. 🟢 marker_6_target keeps the ER’s “No established target; change from own baseline is tracked” rather than inventing a numeric range.
1.3 The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). 🟢 Pregnancy/breastfeeding remains a contraindication, not a caution; the eight interaction bullets remain interactions.
1.4 The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. 🟢 No content from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates, benefits, or risks cards.
1.5 PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. 🟢 No PMIDs, NCT identifiers, author names, or brand names (Suntheanine, AlphaWave) appear anywhere in the QRS.
1.6 The QRS does not introduce new attributions. 🟢 The ER’s “Northumbria University group” attribution for the caffeine pairing is dropped rather than replaced.

2. Focus, Tone & Audience

# Description Result Comments
2.1 The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. 🟢 Measured, non-promotional register carried over from the ER, including the ER’s own “The safety picture is unusually clean.”
2.2 The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging 🟢  
2.3 The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor 🟢  
2.4 The QRS avoids language that implies medical or clinical advice 🟢 No prescriptive verbs (“should”, “must”, “recommended”, “advised”) appear in the body.
2.5 The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” 🟢 Protocol cells state doses as observed practice; risk-mitigation instructions from the ER are not imported.
2.6 The QRS never addresses “the reader” directly — it presents evidence, not guidance 🟢 No second-person pronouns anywhere in the file.
2.7 The QRS is written in plain language, avoiding unnecessary medical jargon 🟢  
2.8 Information is presented in a concise and very compact manner 🟢 Gate and tier items are single short clauses; monitoring rows are trimmed to the essential.
2.9 It DOES NOT address the reader directly 🟢 Confirmed by search for “you”/”your”.
2.10 The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. 🟢  
2.11 The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. 🟢 Monitoring card assumes questionnaires, wearable sleep capture, and repeated blood-pressure readings.
2.12 The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. 🟢  
2.13 Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. 🟢 The reduced-total-sleep-time signal is retained under Medium risk and mirrored in the monitoring row, which is the distinction that matters to this audience.
2.14 The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. 🟢 The string “anti-aging” does not occur; the header uses “Health & Longevity”.
2.15 The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. 🟢 “beats per minute”, “symptomatic hypotension”, “central nervous system depressants”, “general anaesthesia” throughout.

3. Template Integrity

# Description Result Comments
3.1 The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” 🟢 All headings, gate labels, tier labels, and column headers match [qrs_template] byte-for-byte.
3.2 All “…” from the [qrs_template] are present in the the QRS. 🟢 All 34 distinct template variables present; the repeatable marker_#_* and qualitative_item_# rows are expanded to 6 markers and 5 qualitative items.
3.3 Spans that are not addressed in a checklist item are left unchanged 🟢 Diff of the head, CSS block, and body scaffolding against [qrs_template] shows no changes outside variable regions; <span website="evidence_review">, <span website="audit">, <span website="full_review">, and the footer disclaimer are untouched.

4. Formatting

# Description Result Comments
4.1 When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” N/A No source ER section is empty. The ER’s High-risk subsection carries explanatory prose (“No risk reaches High: …”), and its QRS handling is governed by item 13.5, which forbids empty-state phrasing.
4.2 Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. 🟢 All three protocol labels and all eight interaction labels reproduce the ER’s bold labels verbatim.
4.3 Labels are not paraphrased, abbreviated, or invented. 🟢 Monitoring marker names reproduce the ER biomarker column verbatim; tier and gate labels are unmodified.
4.4 The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. 🟢 No emoji in the file; the ER’s “⚠️ Conflicted” markers are dropped, with tiering conveyed by the bold tier labels and card CSS.
4.5 The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. 🟢 Interaction example-drug lists, the salivary-cortisol target, and the monitoring cadence are all trimmed relative to the ER; total estimated flow fits within the 12 mm-margin A4 print area.

5. Metadata

# Description Result Comments
5.1 The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. 🟢 Lines 2–14; the comment opens immediately after <!doctype html> on line 1.
5.2 Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. 🟢 Opening --- line 3, closing --- line 13; the “QRS — Metadata” caption precedes the opening delimiter.
5.3 The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. 🟢 Enclosed in an HTML comment; no metadata value is repeated in the header or footer.
5.4 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5 The filename of the source ER is stated as “er_filename: [er_filename]” 🟢 er_filename: l_theanine_2026-0828-0001_Opus_ER.md, which resolves to the actual ER.
5.6 Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” 🟢 qrs_prompt_version: 26.7.02, matching the version badge in QRS.md.
5.7 Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) 🟢 qrs_creation_date: 2026-0828-1651.
5.8 The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” 🟢 qrs_creator_ai_nickname: Opus.
5.9 The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) 🟢 Single word, no version.
5.10 The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” 🟢 qrs_creator_ai_fullname: Opus 5.
5.11 The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) 🟢 “Opus 5” — nickname plus version, no qualifier.
5.12 The filename of the document is stated as “qrs_filename: [filename of this document]” 🟢 qrs_filename: l_theanine_2026-0828-0001_Opus_QRS.html, matching the file on disk.
5.13 All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. 🟢 Re-verified across all eleven keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

# Description Result Comments
6.1 [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &) 🟢 “L-Theanine for Health & Longevity - Quick Reference Sheet”; ampersand correctly entity-encoded.
6.2 [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &) 🟢 “L-Theanine for Health & Longevity”, matching canonical_topic in the ER frontmatter.
6.3 [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] 🟢 2026-0828-1651 → “08/28/2026”.
6.4 [header_subline_model] is set to [qrs_creator_ai_fullname] 🟢 “Opus 5”.
6.5 No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. 🟢 The ER’s “Also known as” line is not carried over; the subline holds only the template’s own date/model text.

7. At-A-Glance Section

# Description Result Comments
7.1 [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section 🟢 Compresses the Conclusion’s four load-bearing points: what it is, where the strongest returns are, where effects are weaker, and the safety verdict.
7.2 [at_a_glance] is no longer than 60 words 🟢 53 words.
7.3 Every fact in [at_a_glance] is supported by a distinct passage in the ER. 🟢 Each clause maps to a sentence in the ER Conclusion; “The safety picture is unusually clean” is verbatim.
7.4 It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead 🟢 Plain vocabulary only (“amino acid”, “calm alertness”, “reaction speed”); no clinical-register words such as “adjunctive” or “potentiate”.
7.5 It DOES NOT cite specific trials (names, years, sample sizes, p-values) 🟢 No author names, years, sample sizes, or p-values.
7.6 It DOES NOT cite effect sizes, relative risks, or statistical results 🟢 No SMDs, odds ratios, or confidence intervals; effect strength is described qualitatively.

8. Contraindications

# Description Result Comments
8.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 Sourced from the “Populations who should avoid L-Theanine” list at the end of that ER section.
8.2 [stop_items] represent the Contraindications from the ER 🟢 All four ER avoid-populations present: pregnancy/breastfeeding, symptomatic hypotension, children with active tic disorder, pre-surgical window.
8.3 Individual [stop_items] are formatted as <li></li> 🟢 Four <li> elements inside the stop_items span.
8.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 The ER’s trailing rationales (“on the basis of animal placental and breast-milk transfer…”, “in line with standard supplement-hold practice”) are stripped; no dash-led trailing clauses remain.
8.5 Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 The 90 mmHg threshold, orthostatic symptoms, two-or-more-antihypertensives condition, the Tourette qualifier, and the 14-day surgical window are all retained.
8.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s contraindication list uses no ranking notation.
8.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. 🟢 The ER names four such populations and the section is correspondingly populated, not empty.
8.8 If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

9. Key Interactions

# Description Result Comments
9.1 The section is derived from the ER Key Interactions & Contraindications section 🟢 All eight items map one-to-one onto the eight interaction bullets of that ER section.
9.2 [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications 🟢 All eight ER interactions carried; none duplicates one of the four contraindications.
9.3 Individual [caution_items] are formatted as <li></li> 🟢 Eight <li> elements inside the caution_items span.
9.4 Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. 🟢 Each item is a bold label plus a bare drug/agent list; the ER’s consequence and mitigation clauses are all stripped.
9.5 Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). 🟢 Named exemplars retained and trimmed rather than dropped (e.g., lisinopril/losartan/amlodipine; alprazolam/zolpidem; diphenhydramine/doxylamine; sauna/hot bathing/prolonged standing).
9.6 When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. N/A The ER’s interaction bullets use no ranking notation.
9.7 The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. 🟢 The ER identifies eight and the section is correspondingly populated, not empty.
9.8 If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. N/A The section is not empty.

10. Protocol

# Description Result Comments
10.1 The section is derived from the ER Protocol section 🟢 All three cells map onto the first three bullets of the ER Therapeutic Protocol section.
10.2 The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section 🟢 Standard daily, situational acute, and caffeine-pairing are the ER’s three named dosing regimens; the remaining bullets are modifiers or commercial notes rather than distinct regimens.
10.3 If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER provides three or more distinct actionable aspects; all three sets are used.
10.4 All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. 🟢 All nine cells populated: labels verbatim, values carrying the ER dose figures, subs carrying food/timing/duration detail from the same bullets.

11. Time to Effect

# Description Result Comments
11.1 The three sets of [time] items cover the three most important time-to-effect aspects from the ER 🟢 Attention/reaction time, sleep quality, and perceived stress are exactly the three outcomes named in the ER’s “Time to effect” bullet.
11.2 The sets are picked and ordered by the magnitude of the related benefit 🟢 Attention (High tier, SMD 0.51) then sleep quality (High tier, SMD 0.43) then perceived stress (Low tier, SMD 0.31).
11.3 If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. N/A The ER names three distinct time-to-effect aspects; all three sets are used.
11.4 All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. 🟢 All nine cells populated; “30–60 minutes”, “14–28 days”, and the “measurable at 14 days, clearer at 28” gloss all come from the ER Practical Considerations bullet.
11.5 If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel N/A The ER provides time-to-effect information, so the section is retained.

12. Benefits

# Description Result Comments
12.1 The section is derived from the ER Expected Benefits section 🟢 All nine listed benefits correspond to the nine #### headings under the ER’s High/Medium/Low/Speculative tiers.
12.2 Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] 🟢 All four spans present and populated, tier for tier, with no cross-tier migration.
12.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Bare semicolon-separated headings only; no SMDs, confidence intervals, mechanisms, or the ER’s “⚠️ Conflicted” qualifier.
12.4 Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 The ER’s parentheticals (“hallucinations and delusions”, “sugar-damaged proteins”) do not appear.
12.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. N/A All four ER benefit tiers contain items, so no benefits span needs hiding.

13. Risks

# Description Result Comments
13.1 The section is derived from the ER Potential Risks & Side Effects section 🟢 All seven listed risks correspond to the #### headings under the ER’s Medium/Low/Speculative tiers.
13.2 Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] 🟢 All four spans present; three populated and risks_high hidden.
13.3 Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. 🟢 Bare semicolon-separated headings; the ER’s “⚠️ Conflicted” markers, p-values, and 1-in-98 incidence figure are all absent.
13.4 Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. 🟢 The ER’s parentheticals (“blood pressure low enough to cause light-headedness or fainting”, “a sedative drug class”) do not appear.
13.5 If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. 🟢 The ER states “No risk reaches High”, and the QRS renders <span data-qrs-var="risks_high" style="display: none"></span> with no empty-state text.

14. Monitoring

# Description Result Comments
14.1 The section is derived from the ER Monitoring section 🟢 Rows and cadence both taken from the ER Monitoring Protocol & Defining Success section.
14.2 All measurable/quantifiable biomarkers from the Monitoring section are listed 🟢 All six rows of the ER biomarker table are present in order, with names and functional ranges reproduced.
14.3 [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. 🟢 Baseline, 4- and 12-week questionnaire/wearable capture, 2- and 12-week blood-pressure recheck under antihypertensives, and annual thereafter — all matching the ER’s ongoing-monitoring paragraph.

15. Qualitative Assessment

# Description Result Comments
15.1 The section is derived from the ER Monitoring section 🟢 Taken from the ER’s qualitative-markers bullet list at the end of Monitoring Protocol & Defining Success.
15.2 All subjective/qualitative biomarkers from the Monitoring section are listed 🟢 All five ER qualitative markers present verbatim, in the ER’s order.

Issues 28/08/2026 17:12

Pass rate 100.00%. No issues found.

Issues 28/08/2026 17:05

  1. 7.4 — Research jargon in At-A-Glance: “Best-replicated returns” (QRS line 435) carries the research-methods sense of “replicated”; the At-A-Glance rule requires plain-language terms a non-specialist would use unprompted and know exactly.

Fixes 28/08/2026 17:05

  1. 7.4 — Plain-language At-A-Glance phrasing: Replaced “Best-replicated returns:” with “Strongest and most consistent gains:” in the at_a_glance span, removing the research-methods sense of “replicated”; the summary remains within the 60-word budget at 53 words.

Issues 28/08/2026 16:57

  1. 4.5 — Sheet overruns one A4 page: At A4 print geometry (~703px x ~1032px usable) the stacked blocks total roughly 1,750px — about 1.7 pages. The Key Interactions gate wraps to ~16 lines (QRS lines 589-613) and the Monitoring table plus cadence to ~19 lines (QRS lines 656-736), with no section condensed to its per-section budget.

Fixes 28/08/2026 16:57

  1. 4.5 — Key Interactions drug lists trimmed: Shortened the example agent lists in every caution item (e.g. antihypertensives from five drugs to lisinopril, losartan, amlodipine, sedative supplements from seven to four), keeping at least one representative agent per class as item 9.5 requires.
  2. 4.5 — At-A-Glance condensed: Reworded the summary from 57 to 50 words, dropping one wrapped line without losing any Conclusion-derived fact.
  3. 4.5 — Protocol and Time-to-Effect subs shortened: Reduced all three action_#_sub and all three time_#_sub cells to a single wrapped line each (e.g. time_1_sub from “Attention and calming effects appear after a single dose” to “Appears after a single dose”).
  4. 4.5 — Benefits and Risks Low tiers compressed: Trimmed the Low benefit and Low risk lines to one wrapped line each by removing redundant modifiers (“response”, “under mental stress”, “with sleep-promoting agents”).
  5. 4.5 — Contraindication items tightened: Shortened the hypotension and tic-disorder items (“resting systolic” → “systolic”, “two or more” → “2+”, “until a clinician has reviewed the case” → “until clinician review”) while keeping the 90 mmHg threshold and both qualifiers.
  6. 4.5 — Monitoring target and cadence shortened: Condensed marker_6_target to “No established target; change from own baseline is tracked” and the cadence line to the 4/12-week and 2/12-week schedule plus “annual thereafter”.